Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

Akari’s lead program, AKTX-101, a TROP2-targeting ADC powered by its proprietary PH1 payload, is currently in IND-enabling ...

Akari Therapeutics Plc: Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator ...

Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth

Gelteq Limited (“Gelteq”) today announced that it has secured strategic debt financing of up to USD $3.5 million to accelerate its commercialization, expand clinical trial activity and execute on ...